The U.S. Food and Drug Administration has granted Breakthrough Device designation to DISCERN, a biomarker test for Alzheimer’s. The test was developed using blood and tissue samples that were monitored and evaluated by WVU’s Rockefeller Neurosciences Institute. If the test gains full approval, it will be the first FDA-approved test using multiple biomarkers to identify Alzheimer’s Disease …
Input your search keywords and press Enter.
Recent Comments